AOD 9604 (Advanced Obesity Drug 9604) is a modified fragment of human growth hormone (hGH) consisting of amino acids 176-191 from the C-terminal region. This synthetic peptide analog was specifically engineered to retain the potent fat-reducing effects of hGH while eliminating its growth-promoting and insulin-dysregulating properties. AOD 9604 represents a significant advancement in selective lipolytic peptide research and metabolic regulation studies without affecting blood glucose or IGF-1 levels.

Research Applications & Scientific Mechanisms:

🔥 Lipolysis & Fat Metabolism Research:

Stimulates lipolysis (breakdown of fat) through beta-3 adrenergic receptor activation
Inhibits lipogenesis (formation of new fat) in adipose tissue
Mimics natural hGH fat metabolism without growth hormone side effects
Enhances triglyceride breakdown and fatty acid oxidation
Research applications in obesity, body composition, and metabolic disorders

⚡ Energy Expenditure & Thermogenesis Studies:

Increases basal metabolic rate without stimulant effects
Promotes fatty acid beta-oxidation in mitochondria
Enhances energy utilization from stored adipose tissue
Does not affect carbohydrate metabolism or glucose homeostasis
Research applications in weight management and energy balance

💪 Body Composition & Lean Mass Research:

Selective fat reduction without muscle catabolism
Preserves lean body mass during caloric restriction studies
Reduces visceral and subcutaneous adipose tissue
Does not stimulate IGF-1 production or longitudinal bone growth
Research applications in sarcopenic obesity and body recomposition

🧬 Safety & Receptor Selectivity Research:

No effect on insulin sensitivity or glucose metabolism
Does not bind to growth hormone receptors
Minimal impact on IGF-1 levels (safe long-term research profile)
No documented mitogenic or proliferative effects
Research applications in metabolic safety and selective receptor targeting

🔬 Cartilage & Joint Repair Research:

Demonstrated cartilage regeneration properties in osteoarthritis models
Stimulates chondrocyte proliferation and matrix synthesis
Reduces inflammatory markers in joint tissue
Enhances collagen production in cartilage cells
Research applications in osteoarthritis and joint degeneration studies

🩺 Clinical Translation & Human Studies:

Completed Phase II clinical trials for obesity treatment
Demonstrated significant fat loss without adverse metabolic effects
Well-tolerated with minimal side effects in human subjects
Oral bioavailability research showing promising absorption
Research applications in translational medicine and therapeutic development

Published Research Evidence:

Reduces body fat mass by 50% in animal obesity models compared to controls
Maintains stable blood glucose and insulin levels during treatment periods
Demonstrates no effect on IGF-1 or growth hormone receptor activation
Shows cartilage-protective and regenerative effects in osteoarthritis studies
Human trials demonstrate significant fat loss with excellent safety profile
No reported hypoglycemia, proliferative effects, or growth disturbances

Product Specifications:

Purity: ≥98% (HPLC/MS verified)
Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular Weight: 1815.1 g/mol
Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (hGH fragment 176-191, modified)
Format: Lyophilized white to off-white powder
Storage: -20°C (long term), 2-8°C (short term after reconstitution)
Stability: 24-36 months when stored properly in lyophilized form
Reconstitution: Bacteriostatic water or sterile water for injection
pH Range: 4.5-6.5 after reconstitution
Solubility: Highly water soluble
Endotoxin Level: <1.0 EU/mg